The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of first-line molecular targeted agents on the efficacy of second-line bevacizumab-containing regimen for metastatic colorectal cancer.
 
Hiroko Hasegawa
No Relationships to Disclose
 
Hiroya Taniguchi
Honoraria - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda
 
Seiichiro Mitani
No Relationships to Disclose
 
Azusa Komori
No Relationships to Disclose
 
Toshiki Masuishi
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Takeda
 
Yukiya Narita
No Relationships to Disclose
 
Shigenori Kadowaki
No Relationships to Disclose
 
Takashi Ura
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Merck Serono
Consulting or Advisory Role - Janssen; Ono Pharmaceutical
 
Masashi Andoh
No Relationships to Disclose
 
Kei Muro
Honoraria - Chugai Pharma; Takeda; Yakult Honsha
Consulting or Advisory Role - Takeda